**Title:** **Silent brain infarcts on diffusion-weighted imaging after carotid revascularisation: a surrogate outcome measure for procedural stroke? A systematic review and meta-analysis**

Running Title:
**Silent brain infarcts in carotid interventions**

Authors and Affiliations:
Christopher Traenka1, Stefan T Engelter1,4, Martin M Brown2, Joanna Dobson3, Chris Frost3, Leo H Bonati1,2

1 Stroke Center and Department of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland

2 Stroke Research Group, Department of Brain Repair & Rehabilitation, UCL Institute of Neurology, Queen Square, London.

3 Department of Medical Statistics, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK

4 Neurorehabilitation Unit, University of Basel and University Center for Medicine of Aging and Rehabilitation, Felix Platter Hospital, Basel, Switzerland

Corresponding Author:

Leo Bonati, MD

Stroke Center and Department of Neurology

Department of Clinical Research

University Hospital Basel

University of Basel

Petersgraben 4

CH-4031 Basel

Switzerland

Email: leo.bonati@usb.ch

Tel. direct: 0041-61-556-5442

Fax: 0041-61-265-5544

Keywords:
Carotid stenosis - Stenting - Endarterectomy - Stroke - Ischaemic lesions – DWI – Surrogate marker

Word count:

Title: 21

Abstract: 249

Main manuscript: 4350

Disclosures, tables, legends: 927

References: 5899

List of tables and figures

Tables: 1

Figures: 6

Supplementary Tables: 2

Supplemental methods section: 1

Number of references: 196

**Abstract:**

**Aim:** Toinvestigate whether lesions on diffusion-weighted imaging (DWI+) after carotid artery stenting (CAS) or endarterectomy (CEA) might provide a surrogate outcome measure for procedural stroke.

**Methods**: Systematic MedLine® database search with selection of all studies published up to the end of 2016 in which DWI scans were obtained before and within 7 days after CAS or CEA. The correlation between the underlying log odds of stroke and of DWI+ across all treatment groups (i.e. CAS or CEA groups) from included studies was estimated using a bivariate random effects logistic regression model. Relative risks of DWI+ and stroke in studies comparing CAS vs. CEA were estimated using fixed-effect Mantel-Haenszel models.

**Results**: We included data of 4871 CAS and 2099 CEA procedures (85 studies). Across all treatment groups (CEA+CAS), the log odds for DWI+ was significantly associated with the log odds for clinically manifest stroke (correlation coefficient 0.61 [95% CI 0.27 to 0.87], p=0.0012). Across all CAS groups the correlation coefficient was 0.19 (p=0.074). There were too few CEA groups to reliably estimate a correlation coefficient in this subset alone. In 19 studies comparing CAS vs. CEA the relative risks (95% confidence intervals) of DWI+ and stroke were 3.83 (3.17-4.63, p<0.00001) and 2.38 (1.44-3.94, p=0.0007), respectively.

**Discussion and Conclusion:** These findings strengthen the evidence base for the use of DWI as a surrogate outcome measure for procedural stroke in carotid revascularization procedures. Further randomised studies comparing treatment effects on DWI lesions and clinical stroke are needed to fully establish surrogacy.

**Introduction**

Atherosclerotic stenosis of the internal carotid artery is a major cause of stroke. Early randomised trials demonstrated that carotid endarterectomy (CEA) reduces stroke risk in patients with symptomatic and asymptomatic carotid stenosis.[1-4](#_ENREF_1) In recent years, carotid angioplasty and stenting (CAS) has emerged as an alternative to CEA avoiding general surgical complications and morbidity associated with neck incision, as well as shortening hospital stay. In a systematic review of 11 randomised trials including 5778 patients with symptomatic carotid stenosis, CAS was associated with a higher risk of procedural stroke or death than CEA (8.2% versus 5.0%), although the risk difference between CEA and CAS mainly concerned minor strokes which did not lead to disability or death and was seen in patients older than 70 years only.[5](#_ENREF_5), [6](#_ENREF_6) Conversely, CAS avoided cranial nerve palsy and was associated with lower risks of access site hematoma and myocardial infarction. Both treatments appear to be equally effective at preventing recurrent stroke after the procedural period.[7-10](#_ENREF_7)

Further development of surgical and interventional techniques and optimisation of patient selection may lead to a reduction in the risk of procedural stroke associated with carotid revascularisation. However, phase III trials of new carotid interventions designed to show improvement in treatment safety will require many patients and take a long time to complete. For example, a clinical trial would require about 2000 patients to detect a true reduction in the risk of procedural stroke from 6% to 3% with a new intervention compared to an established intervention, at a significance level of 5% and 90% power. The use of a surrogate outcome measure, defined as “a variable that provides an indirect measurement of effect in situations where direct measurement of clinical effect is not feasible or practical”[11](#_ENREF_11) may therefore be justified to investigate new interventions in proof-of-concept or phase II studies and inform the decision whether a large phase III trial should be initiated.[12](#_ENREF_12)

A large number of small to medium sized studies have reported acute cerebral ischaemic lesions on diffusion-weighted magnetic resonance imaging (DWI) to occur in a substantial proportion of patients after treatment of carotid stenosis by CAS or CEA (figure 1). Recent review articles highlighted the potential of DWI as a surrogate safety outcome measure in clinical trials of carotid interventions.[13-15](#_ENREF_13). Furthermore, the existing evidence has never been systematically reviewed in the context of validating ischaemia on DWI as a surrogate outcome measure for procedural ischaemic stroke.

In general, the strength of evidence for a validated surrogate outcome measure depends on the following criteria: Firstly, the biological plausibility of a relationship between the surrogate and the clinical outcome measure; secondly, the demonstration of a correlation between the occurrence of the surrogate and the clinical outcome measure; and thirdly, evidence from clinical trials that the effect of treatment on the surrogate outcome measure (e.g., the relative risk of cerebral ischaemia on DWI in CAS vs. CEA) correlates with the treatment effect on the clinical outcome measure (e.g., the relative risk of procedural stroke in CAS vs. CEA).[11](#_ENREF_11) Based on its specificity to image processes in the brain directly linked to cellular hypoxia, and its sensitivity in detecting acute cerebral ischaemia,[16-18](#_ENREF_16) the use of DWI as a surrogate outcome measure for procedural ischaemic stroke seems biologically plausible. In order to explore the second and third criterion for surrogacy, we performed a systematic literature review and meta-analysis. We investigated the association between the risk of procedural stroke and the risk of cerebral ischaemia on DWI in patients treated by CAS or CEA, and compared the effect of CAS versus CEA on the risk of stroke and the risk of cerebral ischaemia on DWI.

**Methods**

*Search strategy and study eligibility criteria*

A systematic MedLine® search was conducted to identify all studies investigating patients undergoing treatment of carotid artery stenosis by CAS or CEA with DWI, published online with access to the full article or *in-print* version up to December 31st of 2016. The search term (“carotid endarterectomy” OR “carotid stenting” OR “carotid angioplasty”) AND (“DWI” OR “diffusion” OR “MRI” OR “embolism” OR “ischemia” OR “silent” OR “ischemic lesion” OR “emboli”) was entered on <http://www.ncbi.nlm.nih.gov/PubMed>. We also checked cited studies in retrieved articles and existing reviews on MRI in carotid interventions. [13-15](#_ENREF_13), [19](#_ENREF_19)

Studies were included in the analysis if they fulfilled the following criteria: (1) Patients were treated for atherosclerotic carotid stenosis (any degree of stenosis, symptomatic or asymptomatic stenosis) with either CEA or CAS (with or without use of cerebral protection devices); (2) patients were examined with DWI both before and within 7 days after treatment; and (3) the numbers or percentages of patients with new lesions on DWI after treatment and procedural ischaemic stroke were reported. If several publications resulted from the same cohort of patients, we chose the report which included the highest number of patients. Studies assessing brain ischaemia on magnetic resonance imaging (MRI) sequences other than DWI were not included. Studies with prospective or retrospective design were included as long as they fulfilled the inclusion criteria above. Reports on single cases were not included. Likewise, studies reporting on emergency procedures (i.e. including intracranial thrombectomy in acute ischemic stroke) were not included. Two researchers (CT and LHB) reviewed the abstracts of all publications identified by the search, retrieved the full publications where abstract data were consistent with the inclusion criteria, and selected the studies for inclusion based on the full published data.

*Data extraction*

Data was extracted independently by three researchers (LHB, CT and STE). Any disagreement was resolved by consensus. For all eligible studies we extracted: the number (N) of included CAS or CEA procedures; N patients with symptomatic carotid stenosis, usually defined as ischaemic ocular or cerebral symptoms having occurred in the dependent territory of the carotid artery within the past 6 months; magnetic field strength (tesla) used in MRI; latency between treatment and post-treatment DWI; N patients with a positive DWI (henceforward referred to as “DWI+”), defined as the presence of at least one hyperintense lesion on DWI after treatment which was not present on the pre-treatment DWI; and N patients with procedural ischaemic cerebral stroke (henceforward referred to as “stroke”), defined as a focal neurological deficit of probable ischaemic vascular cause lasting >24 hours occurring up to 30 days after treatment, with exclusion of intracranial haemorrhage, hyperperfusion syndrome and other structural brain disease on neuroimaging. Pure retinal infarction was not included. Transient ischaemic attack was not consistently recorded in the studies and was therefore not extracted.

For studies involving CAS, we extracted information on whether a cerebral protection device (CPD) was used and which type of device. For studies involving CEA, we noted whether a standard or eversion technique, a shunt, or a patch was used, and if the procedure was done under local or general anaesthesia. For studies including two or more treatment groups (e.g., studies comparing CAS vs. CEA or studies comparing CAS with vs. without CPD use), data were extracted for each treatment group separately.

Corresponding authors were contacted via e-mail if the published data was not sufficient to determine whether the study was eligible for analysis or not, or to extract the relevant information. Additional data obtained in this way (n=5 studies) was also considered in this review.

*Statistical analysis*

To explore the second criterion for surrogacy, we included all groups of patients treated with CAS or CEA from eligible studies for which the proportion or number of patients with DWI+ and procedural stroke was reported (henceforth referred to as “treatment groups”) as separate data points. First, a crude correlation coefficient for the association between the observed risks of DWI+ and the observed risks of stroke was calculated across treatment groups. This correlation underestimates the extent of the association between the underlying risks because the imprecision in the observed risks dilutes the association as it does whenever an association is measured between two measurement error-prone variables. To account for this we utilised a bivariate random effects logistic regression model to estimate the correlation between the underlying log-transformed odds (log odds) of stroke and the underlying log odds of DWI+. A detailed description of this model is given in the supplemental methods.

A number of studies compared two or more different revascularisation procedures with each other. Owing to the relatively small size of these studies, the confidence interval surrounding the treatment effects with regard to procedural stroke and DWI+ was wide. For these reasons we refrained from further exploring any correlation between treatment effects on stroke and DWI+ to evaluate the third criterion for surrogacy. Instead, we investigated in a meta-analysis of all studies comparing CAS versus CEA, whether the treatment effect for DWI+ pointed in the same direction as the treatment effect for procedural stroke (i.e. whether the comparison between CAS and CEA using DWI+ as the outcome favoured the same treatment as the comparison using stroke as the outcome). Data were aggregated using fixed-effect Mantel-Haenszel models and treatment effects calculated as risk ratios with 95% confidence intervals (95% CI), using CAS as the reference treatment. We quantified heterogeneity using the I² statistic. *Review Manager* Software (*RevMan, version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014)* was used.

*Reporting Standards*

Data presentation and reporting in this manuscript is done according to the reporting standards of the PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses. [20](#_ENREF_20), [21](#_ENREF_21)

**Results**

*Included and excluded studies*

As of March 30th 2017, the search yielded 2555 results (figure 3). Full publications were retrieved of 164 studies published up to December 31st, 2016. 79 studies were excluded for the following reasons: MRI to detect cerebral ischaemia did not include DWI sequences, or DWI was not done in all patients (n=15);[22-36](#_ENREF_22) no DWI was performed before treatment (n=11);[37-47](#_ENREF_37) post-procedural DWI was performed more than 7 days after treatment (n=3);[48-50](#_ENREF_48) the number of DWI+ patients or procedures could not be extracted (n=6);[51-56](#_ENREF_51) or information on procedural stroke was lacking or patients with procedural stroke were excluded from the analysis (n=6).[49](#_ENREF_49), [57-68](#_ENREF_57) One study was excluded because the analysis was restricted to patients with available 6 months follow-up who constituted less than half of the study population (n=1).[69](#_ENREF_69) One study was excluded since only a pre-selected groups of patients showing micro-embolic signals in transcranial doppler during CEA were included in the final analysis.[70](#_ENREF_70) Another study investigating the use of intravascular ultrasound for carotid plaque characterization was excluded since the additional device by itself may have contributed to the occurrence of DWI+ or stroke.[71](#_ENREF_71) A further 28 studies were excluded because updated reports from the same cohort including a larger number of patients had subsequently been published and included, or because the studies were secondary analyses of previously included studies that contained no additional data relevant for the present review.[72-99](#_ENREF_72)

The remaining 85 studies including 6970 carotid revascularisation procedures (CAS: n=4871; CEA: n=2099) fulfilled all eligibility criteria and were included in the analysis. Fourteen studies investigated DWI lesions in CEA.[100-113](#_ENREF_100) One of these studies retrospectively compared conventional with flow-control-CEA (i.e. clamping of the common carotid artery, the external carotid artery and the superior thyroid artery before dissection of the carotid sheath around the internal carotid artery)[108](#_ENREF_108). Six studies investigated DWI lesions in CAS without CPD,[114-119](#_ENREF_114) one of which using a membrane-covered stent.[119](#_ENREF_119) 38 studies investigated DWI lesions in CAS with CPD [120-157](#_ENREF_120): one study randomly compared membrane-covered versus bare-metal stents[129](#_ENREF_129); one study randomly allocated patients to CAS using flow reversal or distal filter protection,[150](#_ENREF_150); one study randomly assigned to either proximal or distal cerebral protection during CAS[145](#_ENREF_145); one study compared open vs. closed-cell stent type in a randomised design[147](#_ENREF_147); three studies compared CAS with CPD versus CAS without CPD,[158-160](#_ENREF_158); and three compared CAS with filter CPD versus CAS with balloon CPD[161-163](#_ENREF_161) three randomised studies, one of which had a 2x2 factorial design[148](#_ENREF_148); investigated clinical and imaging outcomes of CAS according to different regimens of peri-interventional platelet-inhibition[148](#_ENREF_148), [164](#_ENREF_164) and statin treatment;[144](#_ENREF_144), [148](#_ENREF_148) a further study investigated DWI lesions in CAS using different catheter techniques (use of 7F or 8F catheter or use of a coaxial system with use of a 7F or 8F catheter in conjunction with a 4F or 5F catheter), both with and without using CPD.[165](#_ENREF_165) Nineteen studies compared DWI lesions and clinical outcomes in CEA versus CAS,[166-184](#_ENREF_166) only two of which were randomised.[176](#_ENREF_176), [184](#_ENREF_184) Details of included studies are provided in supplementary table 1.

*Incidence of positive DWI and procedural ischaemic stroke in CAS and CEA*

Data from 85 separate CAS treatment groups reporting on outcomes of 4871 CAS procedures were available from eligible single treatment group and multiple treatment group (comparative) studies combined. Carotid symptom status was available in 3829 CAS procedures, and 2023 of those (53%) were done in symptomatic carotid stenosis. New ischaemic lesions on DWI were found after 1805 procedures (average risk 37%), while procedural ischaemic strokes were reported to have occurred in 131 procedures (2.6%; table 1).

Eligible studies provided data for 34 separate CEA treatment groups including 2099 CEA procedures. For 1877 of these CEA procedures carotid symptom status was available, and 1238 of them (66%) were done in patients with symptomatic carotid stenosis. New DWI lesions were detected after 222 procedures (10.8%) and 30 procedures (1.4%) were complicated by procedural ischaemic strokes (table 1).

*Correlation between risk of cerebral ischaemia on DWI and risk of procedural ischaemic stroke*

The crude risks of DWI+ and stroke observed in all 119 treatment groups (CEA and CAS combined) are displayed in figure 4A. The crude correlation between these risks was 0.29 (p=0.0014). Figure 2 illustrates why this crude correlation underestimates the magnitude of the association between the underlying risks. The correlation between the underlying log odds of DWI+ and the log odds of stroke corrected for this underestimation using the bivariate random effects logistic regression model was 0.61 (95% CI 0.27 to 0.87; p=0.0012). The slope of this relationship was 1.20 (95% CI 0.50 to 2.39), this being an estimate of the change in log odds of DWI+ per 1 unit change in the log odds of stroke. Figure 4B converts this estimated linear relationship between the two log odds ratios into the non-linear relationship between the estimated risks. Within the range of procedural stroke risk of between 2% and 7% reported in previous clinical trials of CEA or CAS for symptomatic and asymptomatic carotid stenosis, new ischaemic lesions on post-procedural scans can be expected to occur in about ten times this proportion. Figure 4B shows that for a particular drug or interventional technique in a future randomised controlled trial postulated to reduce procedural stroke risk from 6% to 3% then the predicted reduction in DWI+ risk would be from 56% to 35%. For a standard two-arm clinical trial, with 90% statistical power to detect a difference that is statistically significant at the 5% level using a two-sided test, this equates to a reduction in sample size from 2004 to 228, almost a 90% reduction.

Including only CAS treatment groups, the crude correlation between DWI+ and stroke was 0.19 and the corrected correlation was 0.27 (95% CI -0.19, 0.66], p=0.24). There were too few studies done on CEA and too little variance in stroke risk between studies to be able to accurately estimate the between study variance in stroke risk (with this actually being estimated as zero). Therefore, the corrected correlation between DWI+ and stroke could not be calculated for CEA.

*Comparison of treatment effects on cerebral ischaemia on DWI and procedural ischaemic stroke*

19 eligible studies compared DWI findings and clinical outcomes between CAS and CEA. Across these studies, the risk of being DWI+ after CAS was 3.83 times that after CEA (95% 3.17 to 4.63; p<0.00001; figure 5) while the risk of ischaemic procedural stroke after CAS was 2.38 times (95%CI 1.44 to 3.94; p=0.0007; figure 6) that after CEA.

**Discussion**

In our systematic review of the literature, new ischaemic lesions on DWI were present on average in 37% of patients following CAS compared to 10.8% of patients after CEA; in contrast, the reported risks of procedural ischaemic stroke were only 2.6% and 1.4%, respectively. Across all groups of patients treated with CAS or CEA, the risk of a positive DWI scan after treatment significantly correlated with the risk of procedural stroke. Among those studies comparing CAS versus CEA, summary treatment effects on the occurrence DWI lesions pointed in the same direction as summary treatment effects on ischaemic stroke, i.e. the risks of both clinical and radiological cerebral ischaemia were increased in CAS compared to CEA. Does the current evidence therefore support the use of DWI as a surrogate outcome measure for procedural safety in trials of carotid interventions?

The statistical methodology involved in validating surrogate markers is complex and controversial.[185](#_ENREF_185) {Fleming, 2012 #534} A set of formal statistical rules for validating surrogate outcome measures has been proposed to reduce observation time in prospective trials of progressive diseases.[186](#_ENREF_186) These rules state among other criteria that the surrogate must predict clinically manifest disease in the future and that the full effect of treatment on the clinical outcome must be explained by the effect of treatment on the surrogate outcome. It is evident that we cannot use these formal criteria to validate DWI lesions as a surrogate outcome measure of procedural stroke in carotid interventions: both the potential surrogate – DWI lesions – and the clinical endpoint – procedural stroke – are *short-term* outcome measures characterising risk of procedure; the major advantage of DWI as a surrogate outcome is that ischaemic brain lesions are much more common than clinically manifest stroke, allowing reductions in the sample size of pilot trials investigating novel approaches in reducing treatment risks (e.g. surgical technique, stent design, CPDs and peri-procedural medication). Hence, we evaluated potential surrogacy of DWI against a set of more general rules defined the ICH Harmonised Tripartite Guideline: Statistical Principals for Clinical Trials.[11](#_ENREF_11)

*Is cerebral ischaemia on DWI a biologically plausible surrogate outcome measure for procedural ischaemic stroke?*

Stroke is the most common serious adverse event occurring in carotid revascularisation procedures. In a meta-analysis of randomised trials comparing CAS versus CEA for symptomatic carotid stenosis, 94% of all strokes occurring within 30 days of CAS and 81% of all strokes occurring within 30 days of CEA were attributable to ischaemic cerebral infarction and the remaining events to intracerebral haemorrhage.[187](#_ENREF_187)

Acute cerebral ischaemia leads to a cascade of events on the biological level, including break-down of electrolyte transport across the cellular membrane with subsequent shift of water from the extracellular to the intracellular space (cytotoxic edema). The reduction in extracellular water causes a decrease in random translational motion of water molecules. Diffusion weighted images are generated by measuring this random motion of water molecules by the effect of magnetic gradients on protons. Areas of reduced water diffusion are shown hyperintense in relation to surrounding normal brain tissue. DWI detects brain ischaemia in more than 90% of patients with the final clinical diagnosis of acute ischaemic stroke, and sensitivity and inter-rater reliability are superior to computer tomography or conventional (T2-weighted or FLAIR) MRI.[18](#_ENREF_18), [188](#_ENREF_188), [189](#_ENREF_189) However, DWI may also show ischaemic lesions in the absence of a stroke: hyperintense brain lesions on DWI may be found in about a third patients with transient ischaemic attacks (TIA).[190](#_ENREF_190), [191](#_ENREF_191) Furthermore, brain ischaemia on DWI without associated focal neurological deficit has been shown in patients with carotid stenosis[192](#_ENREF_192) and following therapeutic or investigational procedures on the heart or the carotid artery[13](#_ENREF_13). DWI therefore identifies a spectrum of acute cerebral ischaemia encompassing asymptomatic lesions, TIA and stroke. Based on its specificity to image processes in the brain directly linked to cellular hypoxia, and its sensitivity in detecting acute cerebral ischaemia, the use of DWI as a surrogate outcome measure for procedural ischaemic stroke seems biologically plausible.

*Does ischaemia on DWI correlate with procedural stroke during carotid interventions?* The result of our analysis including all populations treated with CAS or CEA demonstrates a significant correlation between the true risk of stroke and the true risk of cerebral ischaemia (p=0.0012). A statistically significant association of the potential surrogate and clinical outcome constitutes the basis for a use of the surrogate as an endpoint in clinical trials. Our statistical methodology does not allow us to fully establish surrogacy, however it does go part of the way towards this since it allows the magnitude of the association between the risk of a stroke and the risk of DWI lesions to be estimated, taking account of the fact that imprecision in the estimates of these two risks will tend to dilute the magnitude of the underlying association. The fact that the observed correlation between the underlying log odds ratio is strong (albeit with a wide 95% confidence interval) is encouraging. The steepness of the association, coupled with the fact that the prevalence of DWI lesions is much greater than that of stroke illustrates that substantial sample size reductions for clinical trials may be possible by switching from a clinically-based stroke outcome to MRI-based DWI lesions. Returning to the example given in the introduction, instead of 2000 patients (1000 in each treatment group) needed to detect an underlying 3% absolute difference in procedural stroke risk, just over 200 patients would be needed to detect the corresponding difference in DWI lesion risk. The proof of a significant correlation of a potential surrogate outcome measure and the true clinical outcome is crucial but not sufficient by itself to fully validate surrogacy.

*Does the effect of treatment on ischaemic lesions on DWI correspond to the effect of treatment on procedural stroke?* Despite the corresponding summary treatment effects on DWI lesions and procedural stroke in studies comparing CAS versus CEA, there was no clear relationship between the relative risks of DWI positivity and stroke across these studies. The observed number of strokes was very small in most of these comparative studies and estimated relative risks were surrounded by high confidence intervals. Therefore, despite a strong theoretical background supporting the use of DWI as a surrogate outcome measure for procedural stroke in carotid interventions, and evidence for a correlation of DWI lesions with procedural stroke, the existing evidence is insufficient to assess the relationship between the effect of treatment on DWI lesions and on procedural stroke. More data from randomised clinical trials of carotid revascularisation are required to test this criterion. Apart from comparisons of CAS versus CEA, such randomised trials may also compare various surgical or interventional techniques, such as cerebral protection devices, access routes, or medication. They need to incorporate serial MR imaging including DWI and be of adequate size to detect a sufficient number of clinically manifest strokes. In our experience, a time window of 1-7 days before and 1-3 days after the carotid revascularisation procedure for the pre- and post-procedural scan is suitable to detect new ischaemic brain lesions caused by the procedure while at the same time allowing for enough flexibility in scheduling the scans.

Summarizing data from several studies does imply limitations, most importantly the heterogeneity of the included studies. Firstly, the included studies commonly included both patients with symptomatic and asymptomatic carotid stenosis with the proportion of patients having a symptomatic stenosis ranging between 0% and 100% within subgroups (symptomatic stenosis across studies, 53% of all CAS procedures, and 66% of all CEA procedures). Recently symptomatic carotid stenosis may be more prone to embolization and subsequent DWI+ during CAS or CEA due to instability of the atherosclerotic plaque. Secondly, the included studies did use different time windows for pre- and post-treatment MRI scanning, which may have influenced the rate of post-procedural ischaemic brain lesions detected on DWI. Thirdly, definitions of what constituted a new ischaemic lesion after treatment differed: some studies purely relied on new hyperintense lesions on post-treatment DWI which had not been present before treatment. In other studies, a corresponding hypointense signal on ADC maps was additionally required. However, very small acute ischaemic lesions appearing hyperintense on DWI may not be identified on ADC maps due to limited spatial resolution. Finally, less than half of the included 85 studies clearly stated that either clinical assessment for procedural complications was done by an independent neurologist or outcome event adjudication was performed; lower reported incidence of procedural stroke in the absence of clinical evaluation by a neurologist is a well-known phenomenon. However, the average risk of procedural stroke in studies with reported event confirmation by a neurologist was only slightly higher than in studies without (2.6% vs 2.1%).

The importance of DWI lesions occurring during treatment of carotid stenosis may go beyond being a surrogate of procedural stroke. In a prospective, population-based study investigating the association of silent brain infarcts and neurocognitive decline, silent brain infarcts were associated with a higher risk of dementia and a steeper decline in cognitive function.[193](#_ENREF_193) Silent ischaemic brain lesions following coronary artery bypass grafting[194](#_ENREF_194) and intra-cardiac surgery[195](#_ENREF_195) have also been associated with cognitive decline. Only a few small studies performed both cognitive testing and DWI before and after carotid revascularisation.[38](#_ENREF_38), [86](#_ENREF_86), [105](#_ENREF_105), [196](#_ENREF_196) These studies identified few patients with post-treatment ischaemia on DWI and were unable to demonstrate or refute a relationship between subclinical ischaemia and cognitive decline. An MRI based sub-study within the International Carotid Stenting Study investigated multiple aspects of both the occurrence of new DWI lesions and ischaemic events in the procedural period after randomised assignment to CAS or CEA for symptomatic carotid stenosis.[6](#_ENREF_6) After CAS treatment, there was a significantly higher rate of recurrent stroke or TIA during follow-up among patients with new ischaemic brain lesions on DWI after treatment than among those without new DWI lesions.[98](#_ENREF_98) These findings may suggest that new DWI lesions after CAS could further serve as a marker to identify patients at higher risk for future events.

**Conclusion:** Our findings prove a strong correlation between DWI+ and procedural stroke as clinical outcome measure in carotid interventions. The results of our analyses therefore strengthen the evidence base for the use of DWI+ as a surrogate outcome measure for procedural risk in carotid revascularisation. However, despite including a large number of studies with over 6000 carotid interventions criteria for validation of a surrogate marker are still only partly satisfied. Further, randomised studies comparing treatment effects on DWI lesions and clinical stroke are needed to fully establish surrogacy.

**Disclosures:** The authors report no disclosures relevant to the manuscript. Full disclosures are given in the declaration form.

**Tables**

**Table 1: Average risks of cerebral ischaemia on diffusion-weighted magnetic resonance imaging and procedural ischaemic stroke in carotid artery stenting and carotid endarterectomy**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Treatment groupsN | Included proceduresN | Symptomatic carotid stenosisN (%) \*\*\* | DWI+N (%) | Ischaemic StrokeN (%) |
| Carotid artery stenting \* | 85 | 4871 | 2023/3829 (53) | 1805 (37) | 131 (2.6) |
| Any protection device used | 64 | 3000 | 1225/2674 (46) | 1104 (37) | 78 (2.6) |
| No protection device used  | 14 | 698 | 490/679 (72) | 259 (37.1) | 25 (3.6) |
| Carotid endarterectomy \*\* | 34 | 2099 | 1238/1877 (66) | 222 (10.8) | 30 (1.4) |
| General anaesthesia | 25 | 1418 | 750/1193 (62.9) | 161 (11.4) | 19 (1.3) |
| Local anaesthesia  | 5 | 458 | 318/433 (73.4) | 39 (8.5) | 6 (1.3) |

Table 1, legend: Data from treatment groups reported in 85 different studies are presented as numbers and percentages. CAS, carotid artery stenting; CEA, carotid endarterectomy; DWI+, at least 1 new lesion on diffusion weighted imaging after treatment.

\* Including all CAS treatment groups. In 7 studies, patients were treated with or without the use of cerebral protection devices but data were not reported separately.

\*\* Including all CEA treatment groups. In 2 studies, patients were operated under general or local anaesthesia but data were not reported separately. Two further studies did not report on the type of used anaesthesia .

\*\*\* Carotid symptom status was available in 3829 CAS and 1877 CEA procedures, respectively. Percentages of procedures done on symptomatic stenosis of procedures with known symptom status are presented.

**Supplemental methods:**

Using $π\_{si}$ and$ π\_{di}$ to denote the underlying risks of stroke and DWI+ in the *i*th treatment group and *Ni, Si* and *Di* to denote the observed numbers of patients, patients suffering a stroke and patients classified as DWI+ in that group respectively, the model is specified by the following three equations.

$$S\_{i}\~Binomial\left(N\_{i},π\_{si}\right) \left(1\right)$$

$$D\_{i}-S\_{i}\~Binomial\left(N\_{i} - S\_{i},\left({\left(π\_{di}-π\_{si}\right)}/{\left(1-π\_{si}\right)}\right)\right) (2)$$

$$\left(\begin{matrix}log⁡({π\_{di}}/{\left(1-π\_{di}\right)})\\log⁡({π\_{si}}/{\left(1-π\_{si}\right)})\end{matrix}\right)\~N\left(\left(\begin{matrix}μ\_{d}\\μ\_{s}\end{matrix}\right),\left(\begin{matrix}σ\_{d}^{2}&rσ\_{d}σ\_{s}\\rσ\_{d}σ\_{s}&σ\_{s}^{2}\end{matrix}\right)\right) (3)$$

Equation (1) states that the number of strokes in the *i*th treatment group follows a binomial distribution. Equation (2) states that the number of DWI+ cases among those not suffering a stroke also follows a binomial distribution whose mean is chosen such that the overall risk of being DWI+ in that treatment group is$ π\_{di} \left({π\_{di}=π\_{si}+\left(1-π\_{si}\right)×\left(π\_{di}-π\_{si}\right)}/{\left(1-π\_{si}\right)}\right)$. Equation (3) states that the underlying log odds of the two types of event follow a bivariate normal distribution. This model was fitted using PROC NLMIXED in SAS software, version 9.2 (copyright, SAS Institute Inc., Cary, NC, USA), with 95% confidence intervals for *r* (the correlation coefficient for the association between the two log odds)constructed using the profile likelihood, and the p-value from a likelihood ratio test. Secondary analyses restricted to treatment groups of patients receiving CEA or CAS respectively were also attempted.

To illustrate the effect of imprecision in the two observed risks (DWI+ and stroke) on the association between them we performed a simulation (figure 2). Data from 30 treatment groups with sample sizes typical of those in our data were simulated using the model defined above with parameters taken to be similar to the parameter estimates from the model using all included studies.

To estimate the change in sample size requirements for a future clinical trial that can be achieved by switching the primary outcome from stroke risk to DWI+ risk it is necessary to convert a postulated effect on stroke risk to one on DWI+ risk. For example, if it is anticipated that a new drug or interventional technique will reduce the risk of procedural stroke from 6% to 3% it is necessary to convert each of these anticipated underlying stroke risks to anticipated underlying DWI+ risks. The sample size of a phase II trial investigating proof of concept of such an intervention could then be calculated to demonstrate the anticipated reduction in DWI+ risk. Estimation of the parameters in the bivariate random effects logistic regression model allows such conversions to be made because equation (3) implies that there is a linear relationship between the underlying log odds of a stroke and the underlying log odds of being DWI+. Specifically, with the underlying log odds of being DWI+ as the dependent variable and the underlying log odds of a stroke the predictor the line passes through the point $\left(\begin{matrix}μ\_{d}\\μ\_{s}\end{matrix}\right) $and its slope is $rσ\_{d}/σ\_{s}.$

|  |  |
| --- | --- |
|  | Supplementary Table 1:List of all included studies investigating carotid artery stenting (CAS) for carotid stenosis. CAS treatment groups of comparative studies (CEA vs. CAS) are also included (see supplementary table 2 for CEA treatment groups from the same study). The total number of treatment groups in each study is provided (i.e. n=2 if CAS subgroup is part of a comparative study (CAS vs. CEA or CAS vs. CAS); N/A: information not available. Outcome data are provided per study including all CAS treatment groups. |
| Author | **Year of first publication** | **Number of treatment groups included in Study, N** | **Number of CAS treatment groups included**  | **Number of CEA treatment groups included**  | **CAS Procedures included in study, N** | **Symptomatic carotid stenoses, N** | **Number of reported ischaemic strokes, N (%)** | **Relative Risk of Ischaemic Stroke (%)** | **Number of reported DWI +, N (%)** | **Relative Risk of DWI+ (%)** | **Use of any Protection Device (Yes / No / both)** |
| *Loevblad* [*116*](#_ENREF_116) | 2000 | 1 | 1 | 0 | 19 | N/A | 2 | 10.5 | 4 | 21.1 | No |
| *Jaeger* [*120*](#_ENREF_120) | 2001 | 1 | 1 | 0 | 20 | 13 | 0 | 0.0 | 5 | 25.0 | Yes |
| *Jaeger* [*117*](#_ENREF_117) | 2002 | 1 | 1 | 0 | 70 | 52 | 1 | 1.4 | 22 | 31.4 | No |
| *Kopp* [*164*](#_ENREF_164) | 2003 | 3 | 3 | 0 | 80 | 13 | 3 | 3.8 | 23 | 28.8 | Both |
| *Schlueter* [*121*](#_ENREF_121) | 2003 | 1 | 1 | 0 | 44 | 13 | 1 | 2.3 | 10 | 22.7 | Yes |
| *Flach* [*166*](#_ENREF_166) | 2004 | 2 | 1 | 1 | 21 | 21 | 1 | 4.8 | 9 | 42.9 | Yes |
| *Garcia-Sanchez* [*167*](#_ENREF_167) | 2004 | 2 | 1 | 1 | 10 | 10 | 0 | 0.0 | 4 | 40.0 | No |
| *Gauvrit* [*158*](#_ENREF_158) | 2004 | 2 | 2 | 0 | 23 | 12 | 1 | 4.3 | 2 | 8.7 | Both |
| *Cosottini* [*159*](#_ENREF_159) | 2005 | 2 | 2 | 0 | 52 | 23 | 1 | 1.9 | 16 | 30.8 | Both |
| *Roh* [*168*](#_ENREF_168) | 2005 | 2 | 1 | 1 | 22 | 18 | 2 | 9.1 | 8 | 36.4 | No |
| *du Mesnil de Rochemont* [*122*](#_ENREF_122) | 2006 | 1 | 1 | 0 | 50 | 50 | 0 | 0.0 | 19 | 38.0 | Yes |
| *Iihara* [*169*](#_ENREF_169) | 2006 | 2 | 1 | 1 | 92 | 33 | 7 | 7.6 | 32 | 34.8 | Yes |
| *Maleux* [*123*](#_ENREF_123) | 2006 | 1 | 1 | 0 | 53 | 17 | 0 | 0.0 | 22 | 41.5 | Yes |
| *McDonnell* [*124*](#_ENREF_124) | 2006 | 1 | 1 | 0 | 110 | 81 | 8 | 7.3 | 23 | 20.9 | Both |
| *Pinero* [*125*](#_ENREF_125) | 2006 | 1 | 1 | 0 | 162 | 122 | 1 | 0.6 | 28 | 17.3 | Yes |
| *Poppert* [*170*](#_ENREF_170) | 2006 | 2 | 1 | 1 | 41 | 18 | 1 | 2.4 | 22 | 53.7 | No |
| *Rosenkranz* [*118*](#_ENREF_118) | 2006 | 1 | 1 | 0 | 27 | 27 | 0 | 0.0 | 8 | 29.6 | No |
| *Grunwald* [*128*](#_ENREF_128) | 2006 | 1 | 1 | 0 | 10 | N/A | 0 | 0.0 | 4 | 40.0 | Yes |
| *Schillinger* [*129*](#_ENREF_129) | 2006 | 1 | 1 | 0 | 14 | 0 | 0 | 0.0 | 1 | 7.1 | Yes |
| *Asakura* [*126*](#_ENREF_126) | 2006 | 1 | 1 | 0 | 45 | 21 | 0 | 0.0 | 20 | 44.4 | Both |
| *Asakura* [*127*](#_ENREF_127) | 2006 | 1 | 1 | 0 | 11 | 7 | 0 | 0.0 | 2 | 18.2 | Yes |
| *El-Koussy* [*161*](#_ENREF_161) | 2007 | 2 | 2 | 0 | 44 | 25 | 2 | 4.5 | 13 | 29.5 | Yes |
| *Faraglia* [*172*](#_ENREF_172) | 2007 | 2 | 1 | 1 | 35 | 11 | 2 | 5.7 | 12 | 34.3 | Yes |
| *Kim* [*162*](#_ENREF_162) | 2007 | 2 | 2 | 0 | 71 | 47 | 3 | 4.2 | 28 | 39.4 | Yes |
| *Lacroix* [*171*](#_ENREF_171) | 2007 | 2 | 1 | 1 | 61 | 21 | 2 | 3.3 | 26 | 42.6 | Yes |
| *Peynirciouglu* [*119*](#_ENREF_119) | 2007 | 1 | 1 | 0 | 13 | 13 | 0 | 0.0 | 1 | 7.7 | No |
| *Rapp* [*130*](#_ENREF_130) | 2007 | 1 | 1 | 0 | 54 | 29 | 2 | 3.7 | 36 | 66.7 | Yes |
| *Tedesco* [*173*](#_ENREF_173) | 2007 | 2 | 1 | 1 | 34 | 18 | 3 | 8.8 | 24 | 70.6 | Yes |
| *Kastrup* [*160*](#_ENREF_160) | 2008 | 2 | 2 | 0 | 243 | 134 | 14 | 5.8 | 144 | 59.3 | Both |
| *Palombo* [*132*](#_ENREF_132) | 2008 | 1 | 1 | 0 | 98 | 30 | 3 | 3.1 | 20 | 20.4 | Yes |
| *Faggioli* [*134*](#_ENREF_134) | 2008 | 1 | 1 | 0 | 59 | 0 | 0 | 0.0 | 34 | 57.6 | Yes |
| *Schofer* [*133*](#_ENREF_133) | 2008 | 1 | 1 | 0 | 59 | 8 | 0 | 0.0 | 19 | 32.2 | Yes |
| *Faraglia* [*137*](#_ENREF_137) | 2008 | 1 | 1 | 0 | 43 | N/A | 1 | 2.3 | 6 | 14.0 | Yes |
| *Ghorab* [*131*](#_ENREF_131) | 2008 | 1 | 1 | 0 | 50 | 31 | 2 | 4.0 | 6 | 12.0 | Yes |
| *Skjelland* [*174*](#_ENREF_174) | 2009 | 2 | 1 | 1 | 28 | N/A | 2 | 7.1 | 6 | 21.4 | Yes |
| *Tedesco* [*135*](#_ENREF_135) | 2009 | 1 | 1 | 0 | 20 | 9 | 0 | 0.0 | 7 | 35.0 | Yes |
| *Zhou* [*175*](#_ENREF_175) | 2009 | 2 | 1 | 1 | 68 | N/A | 2 | 2.9 | 31 | 45.6 | Yes |
| *Taha* [*136*](#_ENREF_136) | 2009 | 1 | 1 | 0 | 98 | 51 | 3 | 3.1 | 42 | 42.9 | Yes |
| *Bonati* [*176*](#_ENREF_176) | 2010 | 2 | 1 | 1 | 124 | 124 | 9 | 7.3 | 62 | 50.0 | Both |
| *Kim* [*165*](#_ENREF_165) | 2010 | 1 | 1 | 0 | 32 | 32 | 0 | 0.0 | 17 | 53.1 | Both |
| *Palombo* [*138*](#_ENREF_138) | 2010 | 1 | 1 | 0 | 111 | N/A | 4 | 3.6 | 33 | 29.7 | Yes |
| *Rosenkranz* [*115*](#_ENREF_115) | 2010 | 1 | 1 | 0 | 147 | 147 | 6 | 4.1 | 43 | 29.3 | No |
| *Wasser* [*177*](#_ENREF_177) | 2010 | 2 | 1 | 1 | 21 | N/A | 2 | 9.5 | 15 | 71.4 | Both |
| *Yamada* [*178*](#_ENREF_178) | 2011 | 2 | 1 | 1 | 56 | 34 | 2 | 3.6 | 23 | 41.1 | Yes |
| *Grunwald* [*114*](#_ENREF_114) | 2011 | 1 | 1 | 0 | 194 | 133 | 2 | 1.0 | 67 | 34.5 | No |
| *Mitsuoka* [*183*](#_ENREF_183) | 2011 | 2 | 1 | 1 | 20 | 17 | 0 | 0 | 10 | 50 | Yes |
| *Uchiyama* [*140*](#_ENREF_140) | 2011 | 1 | 1 | 0 | 19 | 19 | 1 | 5.3 | 15 | 78.9 | Yes |
| *Pinter* [*139*](#_ENREF_139) | 2011 | 1 | 1 | 0 | 31 | N/A | 1 | 3.2 | 5 | 16.1 | Yes |
| *Tulip* [*141*](#_ENREF_141) | 2012 | 1 | 1 | 0 | 34 | 17 | 1 | 2.9 | 17 | 50.0 | Yes |
| *Felli* [*179*](#_ENREF_179) | 2012 | 2 | 1 | 1 | 150 | 12 | 3 | 2.0 | 51 | 34.0 | Yes |
| *Leal* [*142*](#_ENREF_142) | 2012 | 2 | 2 | 0 | 64 | 44 | 0 | 0.0 | 15 | 23.4 | Yes |
| *Capoccia* [*180*](#_ENREF_180) | 2012 | 2 | 1 | 1 | 28 | 0 | 1 | 3.6 | 6 | 21.4 | Yes |
| *Palombo* [*143*](#_ENREF_143) | 2012 | 1 | 1 | 0 | 34 | 9 | 0 | 0.0 | 8 | 23.5 | Yes |
| *Akutsu* [*182*](#_ENREF_182) | 2012 | 2 | 1 | 1 | 41 | 19 | 1 | 2.4 | 14 | 34.1 | Yes |
| *Bijuklic* [*163*](#_ENREF_163) | 2012 | 2 | 2 | 0 | 62 | 25 | 1 | 1.6 | 41 | 66.1 | Yes |
| *Zhou* [*181*](#_ENREF_181) | 2012 | 2 | 1 | 1 | 16 | 8 | 0 | 0.0 | 8 | 50.0 | Yes |
| *Takayama* [*144*](#_ENREF_144) | 2013 | 2 | 2 | 0 | 61 | 28 | 2 | 3.3 | 25 | 41.0 | Yes |
| *Tanemura[151](#_ENREF_151" \o "Tanemura, 2013 #276)* | 2013 | 1 | 1 | 0 | 47 | 23 | 1 | 2.1 | 26 | 55.3 | Yes |
| *Castro-Afonso*[*150*](#_ENREF_150) | 2013 | 2 | 2 | 0 | 40 | 33 | 0 | 0 | 13 | 32.5 | Yes |
| *Cano* [*145*](#_ENREF_145) | 2013 | 2 | 2 | 0 | 60 | 15 | 1 | 1.7 | 39 | 65.0 | Yes |
| *Pini* [*146*](#_ENREF_146) | 2013 | 1 | 1 | 0 | 20 | 13 | 0 | 0.0 | 18 | 90.0 | Yes |
| *Park* [*147*](#_ENREF_147) | 2013 | 2 | 2 | 0 | 91 | 76 | 1 | 1.1 | 36 | 39.6 | Both |
| *Patti* [*148*](#_ENREF_148) | 2013 | 4 (2x2 design) | 2 | 0 | 156 | 22 | 5 | 6.4 | 40 | 33.3 | Yes |
| *Bijuklic* [*149*](#_ENREF_149) | 2013 | 1 | 1 | 0 | 728 | N/A | 8 | 1.1 | 241 | 33.1 | Yes |
| *Gunduz[152](#_ENREF_152" \o "Gunduz, 2014 #496)* | 2014 | 1 | 1 | 0 | 52 | 39 | 2 | 3.8 | 33 | 63.5 | Yes |
| *Huang*[*153*](#_ENREF_153) | 2014 | 1 | 1 | 0 | 126 | 47 | 4 | 3.2 | 33 | 26.2 | Yes |
| *Kuliha[184](#_ENREF_184" \o "Kuliha, 2015 #499)* | 2015 | 2 | 1 | 1 | 77 | 39 | 1 | 1.3 | 38 | 49.4 | Yes |
| *Matsukawa*[*154*](#_ENREF_154) | 2015 | 1 | 1 | 0 | 36 | 24 | 0 | 0 | 11 | 30.6 | Yes |
| *Adhikari*[*155*](#_ENREF_155) | 2016 | 1 | 1 | 0 | 35 | N/A | 2 | 5.7 | 10 | 28.6 | Yes |
| *Kuliha[156](#_ENREF_156" \o "Kuliha, 2016 #503)* | 2016 | 1 | 1 | 0 | 81 | 32 | 0 | 0 | 46 | 56.8 | Yes |
| *Ruffino*[*157*](#_ENREF_157) | 2016 | 1 | 1 | 0 | 23 | 14 | 0 | 0 | 7 | 30.4 | Yes |

|  |  |
| --- | --- |
|  | Supplementary Table 2:List of all included studies investigating CEA for carotid stenosis. CEA subgroups of comparative studies (CEA vs. CAS) are included (see supplementary table 1 for corresponding CAS subgroups). Number of treatment groups displays the total number of subgroups in each study, i.e. n=2 if CEA subgroup is part of a comparative study (CAS vs. CEA or CEA vs. CEA); N/A: information not given |
| Author | **Year of fist publication** | **Number of treatment groups included in study, N** | **Number of CEA treatment groups included, N** | **Number of CAS treatment groups included, N** | **CEA Procedures included in study, N** | **Symptomatic carotid stenoses, N** | **Number of reported ischaemic strokes, N (%)** | **Relative Risk of Ischaemic Stroke (%)** | **Number of reported DWI +, N (%)** | **Relative Risk of DWI + (%)** | **Type of Anaesthesia (Local or General or Both)** |
| *Feiwell* [*100*](#_ENREF_100) | 2001 | 1 | 1 | 0 | 25 | N/A | 0 | 0 | 1 | 4 | Local |
| *Tomczak* [*101*](#_ENREF_101) | 2001 | 1 | 1 | 0 | 51 | 33 | 2 | 3.9 | 6 | 11.8 | N/A |
| *Mueller* [*102*](#_ENREF_102) | 2003 | 1 | 1 | 0 | 33 | 22 | 1 | 3.0 | 9 | 27.3 | General |
| *Flach* [*166*](#_ENREF_166) | 2004 | 2 | 1 | 1 | 23 | 23 | 1 | 4.3 | 2 | 8.7 | General |
| *Garcia-Sanchez* [*167*](#_ENREF_167) | 2004 | 2 | 1 | 1 | 10 | 10 | 1 | 10.0 | 1 | 10.0 | General |
| *Roh* [*168*](#_ENREF_168) | 2005 | 2 | 1 | 1 | 26 | 19 | 0 | 0.0 | 1 | 3.8 | General |
| *Iihara* [*169*](#_ENREF_169) | 2006 | 2 | 1 | 1 | 139 | 92 | 3 | 2.2 | 13 | 9.4 | General |
| *Inoue* [*103*](#_ENREF_103) | 2006 | 1 | 1 | 0 | 72 | 32 | 1 | 1.4 | 3 | 4.2 | General |
| *Poppert* [*170*](#_ENREF_170) | 2006 | 2 | 1 | 1 | 93 | 44 | 2 | 2.2 | 16 | 17.2 | General |
| *Faraglia* [*172*](#_ENREF_172) | 2007 | 2 | 1 | 1 | 40 | 8 | 0 | 0.0 | 3 | 7.5 | Both |
| *Lacroix* [*171*](#_ENREF_171) | 2007 | 2 | 1 | 1 | 60 | 41 | 2 | 3.3 | 7 | 11.7 | General |
| *Tedesco* [*173*](#_ENREF_173) | 2007 | 2 | 1 | 1 | 30 | 22 | 0 | 0.0 | 1 | 3.3 | General |
| *Ogasawara* [*104*](#_ENREF_104) | 2008 | 1 | 1 | 0 | 163 | 118 | 2 | 1.2 | 28 | 17.2 | General |
| *Soinne* [*105*](#_ENREF_105) | 2008 | 1 | 1 | 0 | 44 | 21 | 0 | 0.0 | 2 | 4.5 | General |
| *Skjelland* [*174*](#_ENREF_174) | 2009 | 2 | 1 | 1 | 30 | N/A | 1 | 3.3 | 2 | 6.7 | General |
| *Zhou* [*175*](#_ENREF_175) | 2009 | 2 | 1 | 1 | 100 | N/A | 2 | 2.0 | 12 | 12.0 | General |
| *Bonati* [*176*](#_ENREF_176) | 2010 | 2 | 1 | 1 | 107 | 107 | 3 | 2.8 | 18 | 16.8 | Both |
| *Hebb* [*106*](#_ENREF_106) | 2010 | 1 | 1 | 0 | 50 | 18 | 0 | 0.0 | 0 | 0.0 | General |
| *Wasser* [*177*](#_ENREF_177) | 2010 | 2 | 1 | 1 | 28 | N/A | 0 | 0.0 | 1 | 3.6 | General |
| *Mitsuoka[183](#_ENREF_183" \o "Mitsuoka, 2011 #495)* | 2011 | 2 | 1 | 1 | 25 | 22 | 0 | 0 | 0 | 0 | N/A |
| *Yamada* [*178*](#_ENREF_178) | 2011 | 2 | 1 | 1 | 25 | 16 | 0 | 0.0 | 2 | 8.0 | General |
| *Felli* [*179*](#_ENREF_179) | 2012 | 2 | 1 | 1 | 150 | 138 | 2 | 1.3 | 6 | 4.0 | Local |
| *Capoccia* [*180*](#_ENREF_180) | 2012 | 2 | 1 | 1 | 32 | 0 | 0 | 0.0 | 1 | 3.1 | Local |
| *Akutsu* [*182*](#_ENREF_182) | 2012 | 2 | 1 | 1 | 63 | 34 | 0 | 0.0 | 11 | 17.5 | General |
| *Zhou* [*181*](#_ENREF_181) | 2012 | 2 | 1 | 1 | 35 | 19 | 0 | 0.0 | 3 | 8.6 | General |
| *Oikawa* [*107*](#_ENREF_107) | 2013 | 1 | 1 | 0 | 101 | 101 | 2 | 2.0 | 9 | 8.9 | General |
| *Yoshida* [*108*](#_ENREF_108) | 2013 | 2 | 1 | 0 | 67 | 36 | 0 | 0.0 | 7 | 10.4 | General |
| *Cho* [*109*](#_ENREF_109) | 2013 | 1 | 1 | 0 | 45 | 31 | 0 | 0.0 | 4 | 8.9 | Local |
| *Sfyroeras* [*110*](#_ENREF_110) | 2013 | 1 | 1 | 0 | 66 | 17 | 0 | 0.0 | 5 | 7.6 | General |
| *Akpinar*[*111*](#_ENREF_111) | 2015 | 1 | 1 | 0 | 51 | 28 | 0 | 0 | 8 | 15.7 | General |
| *Kuliha[184](#_ENREF_184" \o "Kuliha, 2015 #499)* | 2015 | 2 | 1 | 1 | 73 | 48 | 1 | 1.4 | 18 | 24.7 | General |
| *Bourke[112](#_ENREF_112" \o "Bourke, 2016 #502)* | 2016 | 1 | 1 | 0 | 206 | 149 | 4 | 1.9 | 27 | 13.1 | Local |
| *Zhang*[*113*](#_ENREF_113) | 2016 | 1 | 1 | 0 | 36 | 25 | 0 | 0.0 | 0 | 0 | General |

**Figure legends:**

**Figure 1:** **Diffusion weighted magnetic resonance imaging (DWI) of a patient following stenting of the right carotid artery.** Multiple hyperintense signals representing acute ischaemic lesions in the territory of the right middle cerebral artery are present. The patient did not experience any symptoms. Copyright Department of Radiology, University Hospital Basel.

**Figure 2:** **Illustrative example of statistical method using simulated data**

A: Simulated “underlying” (true) log odds of DWI+ (i.e. presence of at least one new DWI brain lesion after treatment) and log odds of procedural ischaemic stroke for 30 studies, with regression line. Simulated data was drawn from a bivariate normal distribution with means, SDs and correlation similar to those estimated using the actual data by the bivariate random effects logistic regression model. This plot therefore represents the ‘corrected’ association between log odds of DWI+ and log odds stroke.

B: Conversion of simulated “underlying” log odds of DWI+ and stroke to “underlying” risks of DWI+ and stroke for all 30 studies, with fitted regression line (risk=exp(log odds)/(exp(log odds)+1).

C: Simulation of observed risks (hollow circles) by addition of sampling error (random error; green arrows) to both the “underlying” (true) risks of DWI+ and stroke (solid circles, as in figure B) through sampling subjects in each of the 30 studies (which have sizes typical of the studies included in our analysis). First observed stroke risk was simulated, then it was assumed that everyone who has a stroke is DWI+, and finally the number of DWI+ cases amongst those without stroke was simulated. Size of hollow circles for observed risks is relative to the number of patients in that study. Smaller studies tend to be subject to greater sampling error (as indicated by typically longer arrows).

D: Simulated observed risks of DWI+ and stroke for 30 studies, with fitted regression line. This plot represents the crude association between study-specific DWI+ and stroke risks and demonstrates its underestimation compared with the association of “underlying” (true) DWI+ and stroke risks as in figure B (as both factors are subject to sampling error).

**Figure 3:** **Flow-chart of selection of retrieved studies for analysis.** CAS, carotid artery stenting; CEA, carotid endarterectomy

**Figure 4: Crude risks of cerebral ischaemia on DWI and procedural ischaemic stroke and fitted association between the underlying risks of these outcomes in 119 groups of patients undergoing carotid revascularisation**

A: Observed crude risks of stroke and ischaemia on diffusion weighted imaging (DWI) in all 119 treatment groups. Red triangles represent groups of patients treated with carotid endarterectomy and blue dots groups of patients treated with stents.

B: Fitted regression line relating “underlying” (true) risk of DWI lesions to “underlying” (true) risk of stroke in all included studies. Correlation between log odds of DWI lesions and log odds of stroke (coefficient 0.61 [95% CI 0.27, 0.87], p=0.0012). Red lines show the magnitude of reduction in risk of DWI lesions that might be observed in a pilot trial expected to reduce the risk of procedural stroke from 6% to 3%.

**Figure 5: Meta-analysis of studies comparing the risk of new ischaemic brain lesions on diffusion weighted imaging after carotid artery stenting and carotid endarterectomy.**

Data are numbers of patients with DWI lesions (“events”), total numbers of patients and Mantel-Haenszel fixed-effects risk ratios including 95% confidence intervals (CI), with endarterectomy as the reference treatment. Squares on the right represent point estimates of risk ratios at trial level, with 95% CI as horizontal bars. The diamond at the bottom represents the summary risk ratio and 95% CI.

**Figure 6:** **Meta-analysis of studies comparing the risk of procedural ischaemic stroke between carotid artery stenting and carotid endarterectomy.**

The same studies as in Figure 5 are included. Data are numbers of patients with strokes (“events”), total numbers of patients and Mantel-Haenszel fixed-effects risk ratios including 95% confidence intervals (CI), with endarterectomy as the reference treatment. Squares on the right represent point estimates of risk ratios at trial level, with 95% CI as horizontal bars. The diamond at the bottom represents the summary risk ratio and 95% CI.

**References:**

1. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. *NEnglJ Med*. 1991; 325: 445-53.

2. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). *Lancet*. 1998; 351: 1379-87.

3. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. *JAMA*. 1995; 273: 1421-8.

4. Halliday A, Mansfield A, Marro J, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. *Lancet*. 2004; 363: 1491-502.

5. Bonati LH, Lyrer P, Ederle J, Featherstone R and Brown MM. Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosis. *Cochrane Database SystRev*. 2012; 9: CD000515.

6. Bonati LH, Dobson J, Algra A, et al. Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data. *Lancet*. 2010; 376: 1062-73.

7. Eckstein HH, Ringleb P, Allenberg JR, et al. Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. *Lancet Neurol*. 2008; 7: 893-902.

8. Brott TG, Hobson RW, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. *NEnglJ Med*. 2010; 363: 11-23.

9. Mas JL, Arquizan C, Calvet D, et al. Long-term follow-up study of endarterectomy versus angioplasty in patients with symptomatic severe carotid stenosis trial. *Stroke*. 2014; 45: 2750-6.

10. Bonati LH, Dobson J, Featherstone RL, et al. Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial. *Lancet*. 2015; 385: 529-38.

11. Use ICoHoTRfRoPfH. ICH Harmonised Tripartite Guideline: Statistical Principals for Clinical Trials. 1998.

12. Fleming TR and DeMets DL. Surrogate end points in clinical trials: are we being misled? *AnnInternMed*. 1996; 125: 605-13.

13. Bendszus M and Stoll G. Silent cerebral ischaemia: hidden fingerprints of invasive medical procedures. *Lancet Neurol*. 2006; 5: 364-72.

14. Schnaudigel S, Groschel K, Pilgram SM and Kastrup A. New brain lesions after carotid stenting versus carotid endarterectomy: a systematic review of the literature. *Stroke*. 2008; 39: 1911-9.

15. Cho SM, Deshpande A, Pasupuleti V, Hernandez AV and Uchino K. Radiographic and symptomatic brain ischemia in CEA and CAS: A systematic review and meta-analysis. *Neurology*. 2017; 89: 1977-84.

16. Moseley ME, Cohen Y, Mintorovitch J, et al. Early detection of regional cerebral ischemia in cats: comparison of diffusion- and T2-weighted MRI and spectroscopy. *Magn ResonMed*. 1990; 14: 330-46.

17. Warach S, Chien D, Li W, Ronthal M and Edelman RR. Fast magnetic resonance diffusion-weighted imaging of acute human stroke. *Neurology*. 1992; 42: 1717-23.

18. Lansberg MG, Norbash AM, Marks MP, Tong DC, Moseley ME and Albers GW. Advantages of adding diffusion-weighted magnetic resonance imaging to conventional magnetic resonance imaging for evaluating acute stroke. *ArchNeurol*. 2000; 57: 1311-6.

19. Vermeer SE, Longstreth WT, Jr. and Koudstaal PJ. Silent brain infarcts: a systematic review. *Lancet Neurol*. 2007; 6: 611-9.

20. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic reviews*. 2015; 4: 1.

21. Moher D, Liberati A, Tetzlaff J, Altman DG and Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS medicine*. 2009; 6: e1000097.

22. Jansen C, Ramos LM, van Heesewijk JP, Moll FL, van GJ and Ackerstaff RG. Impact of microembolism and hemodynamic changes in the brain during carotid endarterectomy. *Stroke*. 1994; 25: 992-7.

23. Cantelmo NL, Babikian VL, Samaraweera RN, Gordon JK, Pochay VE and Winter MR. Cerebral microembolism and ischemic changes associated with carotid endarterectomy. *J VascSurg*. 1998; 27: 1024-30.

24. van Heesewijk HP, Vos JA, Louwerse ES, et al. New brain lesions at MR imaging after carotid angioplasty and stent placement. *Radiology*. 2002; 224: 361-5.

25. Terada T, Tsuura M, Matsumoto H, et al. Results of endovascular treatment of internal carotid artery stenoses with a newly developed balloon protection catheter. *Neurosurgery*. 2003; 53: 617-23.

26. Madycki G, Staszkiewicz W and Gabrusiewicz A. Carotid plaque texture analysis can predict the incidence of silent brain infarcts among patients undergoing carotid endarterectomy. *EurJ VascEndovascSurg*. 2006; 31: 373-80.

27. Henry M, Polydorou A, Henry I, et al. New distal embolic protection device the FiberNet 3 dimensional filter: first carotid human study. *CatheterCardiovascInterv*. 2007; 69: 1026-35.

28. Wu YM, Wong HF, Chen YL, Wong MC and Toh CH. Carotid stenting of asymptomatic and symptomatic carotid artery stenoses with and without the use of a distal embolic protection device. *Acta Cardiol*. 2011; 66: 453-8.

29. Huang KL, Ho MY, Chang CH, et al. Impact of silent ischemic lesions on cognition following carotid artery stenting. *EurNeurol*. 2011; 66: 351-8.

30. Almekhlafi MA, Demchuk AM, Mishra S, et al. Malignant emboli on transcranial Doppler during carotid stenting predict postprocedure diffusion-weighted imaging lesions. *Stroke*. 2013; 44: 1317-22.

31. Inoue T, Tsutsumi K, Ohwaki K, et al. Stratification of intraoperative ischemic impact by somatosensory evoked potential monitoring, diffusion-weighted imaging and magnetic resonance angiography in carotid endarterectomy with routine shunt use. *Acta neurochirurgica*. 2013; 155: 2085-96.

32. Enevoldsen EM, Torfing T, Kjeldsen MJ and Nepper-Rasmussen J. Cerebral infarct following carotid endarterectomy. Frequency, clinical and hemodynamic significance evaluated by MRI and TCD. *Acta neurologica Scandinavica*. 1999; 100: 106-10.

33. Akkaya E, Vuruskan E, Gul ZB, et al. Cerebral microemboli and neurocognitive change after carotid artery stenting with different embolic protection devices. *Int J Cardiol*. 2014; 176: 478-83.

34. Berman SE, Wang X, Mitchell CC, et al. The relationship between carotid artery plaque stability and white matter ischemic injury. *Neuroimage Clin*. 2015; 9: 216-22.

35. Corriere MA, Edwards MS, Geer CP, Keith DR, Deal DD and Stump DA. Longitudinal evaluation of neurobehavioral outcomes after carotid revascularization. *Annals of vascular surgery*. 2014; 28: 874-81.

36. Montorsi P, Caputi L, Galli S, et al. Microembolization during carotid artery stenting in patients with high-risk, lipid-rich plaque. A randomized trial of proximal versus distal cerebral protection. *Journal of the American College of Cardiology*. 2011; 58: 1656-63.

37. Muller M, Reiche W, Langenscheidt P, Hassfeld J and Hagen T. Ischemia after carotid endarterectomy: comparison between transcranial Doppler sonography and diffusion-weighted MR imaging. *AJNR AmJNeuroradiol*. 2000; 21: 47-54.

38. Heyer EJ, DeLaPaz R, Halazun HJ, et al. Neuropsychological dysfunction in the absence of structural evidence for cerebral ischemia after uncomplicated carotid endarterectomy. *Neurosurgery*. 2006; 58: 474-80.

39. Gossetti B, Gattuso R, Irace L, et al. Embolism to the brain during carotid stenting and surgery. *Acta Chir Belg*. 2007; 107: 151-4.

40. Barbato JE, Dillavou E, Horowitz MB, et al. A randomized trial of carotid artery stenting with and without cerebral protection. *JVascSurg*. 2008; 47: 760-5.

41. Takayama K, Nakagawa H, Iwasaki S, et al. Initial experience of using the filter protection device during carotid artery stenting in Japan. *RadiatMed*. 2008; 26: 348-54.

42. Gattuso R, Martinelli O, Alunno A, et al. Carotid stenting and transcranial Doppler monitoring: indications for carotid stenosis treatment. *VascEndovascularSurg*. 2010; 44: 535-8.

43. Yamatogi S, Furukawa M, Iida E, et al. Evaluation of small ischemic lesions after carotid artery stenting: the usefulness of thin-slice diffusion-weighted MR imaging. *Neuroradiology*. 2011; 53: 255-60.

44. Chung GH, Jeong JY, Kwak HS and Hwang SB. Associations between Cerebral Embolism and Carotid Intraplaque Hemorrhage during Protected Carotid Artery Stenting. *AJNR American journal of neuroradiology*. 2016; 37: 686-91.

45. Lee EJ, Cho YP, Lee SH, et al. Hemodynamic Tandem Intracranial Lesions on Magnetic Resonance Angiography in Patients Undergoing Carotid Endarterectomy. *J Am Heart Assoc*. 2016; 5.

46. Maruyama D, Fukuda K, Kataoka H, et al. Evaluation of carotid artery outward remodeling by T1-weighted magnetic resonance imaging in carotid endarterectomy and stenting. *J Vasc Surg*. 2015; 61: 1464-71 e1.

47. Mazzalai F, Piatto G, Toniato A, Lorenzetti R, Baracchini C and Ballotta E. Using protamine can significantly reduce the incidence of bleeding complications after carotid endarterectomy without increasing the risk of ischemic cerebral events. *World J Surg*. 2014; 38: 1227-32.

48. Falkensammer J, Oldenburg WA, Hendrzak AJ, et al. Evaluation of subclinical cerebral injury and neuropsychologic function in patients undergoing carotid endarterectomy. *AnnVascSurg*. 2008; 22: 497-504.

49. Takemoto K, Ueba T, Takano K, et al. Quantitative evaluation using the plaque/muscle ratio index panels predicts plaque type and risk of embolism in patients undergoing carotid artery stenting. *Clinical neurology and neurosurgery*. 2013; 115: 1298-303.

50. Wang Q, Zhou M, Zhou Y, Ji J, Raithel D and Qiao T. Effects of Carotid Endarterectomy on Cerebral Reperfusion and Cognitive Function in Patients with High Grade Carotid Stenosis: A Perfusion Weighted Magnetic Resonance Imaging Study. *Eur J Vasc Endovasc Surg*. 2015; 50: 5-12.

51. Posacioglu H, Engin C, Cinar C, et al. Carotid endarterectomy versus carotid artery stenting: findings in regard to neuroclinical outcomes and diffusion-weighted imaging. *TexHeart InstJ*. 2008; 35: 395-401.

52. MacDonald S, Evans DH, Griffiths PD, et al. Filter-protected versus unprotected carotid artery stenting: a randomised trial. *Cerebrovasc Dis*. 2010; 29: 282-9.

53. Timaran CH, Rosero EB, Higuera A, Ilarraza A, Modrall JG and Clagett GP. Randomized clinical trial of open-cell vs closed-cell stents for carotid stenting and effects of stent design on cerebral embolization. *J VascSurg*. 2011; 54: 1310-6.

54. Pinero Gonzalez de la Pena P, Gonzalez Garcia A, Moniche Alvarez F, et al. [Filter content after carotid angioplasty and stenting: relation to ischemic lesions in diffusion-weighted imaging]. *Radiologia*. 2012; 54: 155-64.

55. Grunwald IQ, Reith W, Kuhn AL, et al. Proximal protection with the Gore PAES can reduce DWI lesion size in high-grade stenosis during carotid stenting. *EuroIntervention*. 2014; 10: 271-6.

56. Sakamoto M, Taoka T, Nakagawa H, et al. Magnetic resonance plaque imaging to predict the occurrence of the slow-flow phenomenon in carotid artery stenting procedures. *Neuroradiology*. 2010; 52: 275-83.

57. Barth A, Remonda L, Lovblad KO, Schroth G and Seiler RW. Silent cerebral ischemia detected by diffusion-weighted MRI after carotid endarterectomy. *Stroke*. 2000; 31: 1824-8.

58. Tiemann L, Reidt JH, Esposito L, Sander D, Theiss W and Poppert H. Neuropsychological sequelae of carotid angioplasty with stent placement: correlation with ischemic lesions in diffusion weighted imaging. *PLoSOne*. 2009; 4: e7001.

59. Blasel S, Hattingen E, Berkefeld J, et al. Evaluation of angiographic and technical aspects of carotid stenting with diffusion-weighted magnetic resonance imaging. *CardiovascInterventRadiol*. 2009; 32: 666-71.

60. Kurata M, Okura T, Kumon Y, et al. Plasma thrombin-cleaved osteopontin elevation after carotid artery stenting in symptomatic ischemic stroke patients. *Hypertension research : official journal of the Japanese Society of Hypertension*. 2012; 35: 207-12.

61. Nanba T, Ogasawara K, Nishimoto H, et al. Postoperative cerebral white matter damage associated with cerebral hyperperfusion and cognitive impairment after carotid endarterectomy: a diffusion tensor magnetic resonance imaging study. *Cerebrovasc Dis*. 2012; 34: 358-67.

62. Cho AH, Cho YP, Lee DH, et al. Reperfusion injury on magnetic resonance imaging after carotid revascularization. *Stroke*. 2014; 45: 602-4.

63. Hitchner E, Baughman BD, Soman S, Long B, Rosen A and Zhou W. Microembolization is associated with transient cognitive decline in patients undergoing carotid interventions. *J Vasc Surg*. 2016; 64: 1719-25.

64. Lee JH and Suh BY. Risk factor analysis of new brain lesions associated with carotid endarterectmy. *Ann Surg Treat Res*. 2014; 86: 39-44.

65. Orlicky M, Vachata P, Bartos R, Waldauf P and Sames M. A selective carotid artery shunting for carotid endarterectomy: prospective MR DWI monitoring of embolization in a group of 754 patients. *J Neurol Surg A Cent Eur Neurosurg*. 2015; 76: 89-92.

66. Sahin N, Solak A, Genc B, Akpinar MB, Kulu U and Cengiz H. Brain diffusion changes in unilateral carotid artery stenosis with non-shunt endarterectomy: Correlation with white matter lesions. *Clinical neurology and neurosurgery*. 2015; 133: 24-9.

67. Skoloudik D, Kuliha M, Hrbac T, Jonszta T, Herzig R and Group ST. Sonolysis in Prevention of Brain Infarction During Carotid Endarterectomy and Stenting (SONOBUSTER): a randomized, controlled trial. *Eur Heart J*. 2016; 37: 3096-102.

68. Yoshimura S, Yamada K, Kawasaki M, et al. High-intensity signal on time-of-flight magnetic resonance angiography indicates carotid plaques at high risk for cerebral embolism during stenting. *Stroke*. 2011; 42: 3132-7.

69. Hauth EA, Jansen C, Drescher R, et al. MR and clinical follow-up of diffusion-weighted cerebral lesions after carotid artery stenting. *AJNR AmJNeuroradiol*. 2005; 26: 2336-41.

70. Fujimoto K, Matsumoto Y, Oikawa K, et al. Cerebral Hyperperfusion after Revascularization Inhibits Development of Cerebral Ischemic Lesions Due to Artery-to-Artery Emboli during Carotid Exposure in Endarterectomy for Patients with Preoperative Cerebral Hemodynamic Insufficiency: Revisiting the "Impaired Clearance of Emboli" Concept. *Int J Mol Sci*. 2016; 17.

71. Hitchner E, Zayed MA, Lee G, Morrison D, Lane B and Zhou W. Intravascular ultrasound as a clinical adjunct for carotid plaque characterization. *J Vasc Surg*. 2014; 59: 774-80.

72. Forbes KP, Shill HA, Britt PM, Zabramski JM, Spetzler RF and Heiserman JE. Assessment of silent embolism from carotid endarterectomy by use of diffusion-weighted imaging: work in progress. *AJNR AmJNeuroradiol*. 2001; 22: 650-3.

73. Poppert H, Wolf O, Resch M, et al. Differences in number, size and location of intracranial microembolic lesions after surgical versus endovascular treatment without protection device of carotid artery stenosis. *JNeurol*. 2004; 251: 1198-203.

74. Wolf O, Heider P, Heinz M, et al. Frequency, clinical significance and course of cerebral ischemic events after carotid endarterectomy evaluated by serial diffusion weighted imaging. *EurJVascEndovascSurg*. 2004; 27: 167-71.

75. Wolf O, Heider P, Heinz M, et al. Microembolic signals detected by transcranial Doppler sonography during carotid endarterectomy and correlation with serial diffusion-weighted imaging. *Stroke*. 2004; 35: e373-e5.

76. Gonzalez A, Pinero P, Martinez E, et al. Silent cerebral ischemic lesions after carotid artery stenting with distal cerebral protection. *NeurolRes*. 2005; 27 Suppl 1: S79-S83.

77. Hammer FD, Lacroix V, Duprez T, et al. Cerebral microembolization after protected carotid artery stenting in surgical high-risk patients: results of a 2-year prospective study. *JVascSurg*. 2005; 42: 847-53.

78. Kastrup A, Nagele T, Groschel K, et al. Incidence of new brain lesions after carotid stenting with and without cerebral protection. *Stroke*. 2006; 37: 2312-6.

79. Krapf H, Nagele T, Kastrup A, et al. Risk factors for periprocedural complications in carotid artery stenting without filter protection: A serial diffusion-weighted MRI study. *JNeurol*. 2006; 253: 364-71.

80. Tedesco MM, Lee JT, Dalman RL, et al. Postprocedural microembolic events following carotid surgery and carotid angioplasty and stenting. *JVascSurg*. 2007; 46: 244-50.

81. Aso K, Ogasawara K, Sasaki M, et al. Preoperative cerebrovascular reactivity to acetazolamide measured by brain perfusion SPECT predicts development of cerebral ischemic lesions caused by microemboli during carotid endarterectomy. *EurJNuclMedMolImaging*. 2008.

82. Heider P, Poppert H, Wolf O, et al. Fibrinogen and high-sensitive C-reactive protein as serologic predictors for perioperative cerebral microembolic lesions after carotid endarterectomy. *J VascSurg*. 2007; 46: 449-54.

83. Groschel K, Pilgram SM, Ernemann U, et al. Aortic calcification on plain chest radiography predicts embolic complications during carotid artery stenting. *EurJNeurol*. 2008; 15: 730-6.

84. Kastrup A, Groschel K, Schnaudigel S, Nagele T, Schmidt F and Ernemann U. Target lesion ulceration and arch calcification are associated with increased incidence of carotid stenting-associated ischemic lesions in octogenarians. *JVascSurg*. 2008; 47: 88-95.

85. Grunwald IQ, Papanagiotou P, Roth C, et al. Lesion load in unprotected carotid artery stenting. *Neuroradiology*. 2009; 51: 313-7.

86. Grunwald IQ, Papanagiotou P, Reith W, et al. Influence of carotid artery stenting on cognitive function. *Neuroradiology*. 2010; 52: 61-6.

87. Yamada K, Kawasaki M, Yoshimura S, et al. Prediction of silent ischemic lesions after carotid artery stenting using integrated backscatter ultrasound and magnetic resonance imaging. *Atherosclerosis*. 2010; 208: 161-6.

88. Yamada K, Yoshimura S, Kawasaki M, et al. Prediction of silent ischemic lesions after carotid artery stenting using virtual histology intravascular ultrasound. *CerebrovascDis*. 2011; 32: 106-13.

89. Zhu L, Wintermark M, Saloner D, Fandel M, Pan XM and Rapp JH. The distribution and size of ischemic lesions after carotid artery angioplasty and stenting: evidence for microembolization to terminal arteries. *J VascSurg*. 2011; 53: 971-5.

90. Russjan A, Goebell E, Havemeister S, et al. Predictors of periprocedural brain lesions associated with carotid stenting. *CerebrovascDis*. 2012; 33: 30-6.

91. Gensicke H, Zumbrunn T, Jongen LM, et al. Characteristics of ischemic brain lesions after stenting or endarterectomy for symptomatic carotid artery stenosis: results from the international carotid stenting study-magnetic resonance imaging substudy. *Stroke*. 2013; 44: 80-6.

92. Wasser K, Hildebrandt H, Groschel S, et al. Age-dependent effects of carotid endarterectomy or stenting on cognitive performance. *Journal of neurology*. 2012; 259: 2309-18.

93. Capoccia L, Speziale F, Gazzetti M, et al. Comparative study on carotid revascularization (endarterectomy vs stenting) using markers of cellular brain injury, neuropsychometric tests, and diffusion-weighted magnetic resonance imaging. *J VascSurg*. 2010; 51: 584-91, 91.

94. Leal JI, Orgaz A, Fontcuberta J, et al. A prospective evaluation of cerebral infarction following transcervical carotid stenting with carotid flow reversal. *Eur J Vasc Endovasc Surg*. 2010; 39: 661-6.

95. Altinbas A, Algra A, Bonati LH, et al. Periprocedural hemodynamic depression is associated with a higher number of new ischemic brain lesions after stenting in the International Carotid Stenting Study-MRI Substudy. *Stroke*. 2014; 45: 146-51.

96. Burow A, Lyrer PA, Nederkoorn PJ, et al. Echographic risk index and cerebral ischemic brain lesions in patients randomized to stenting versus endarterectomy for symptomatic carotid artery stenosis. *Ultraschall Med*. 2014; 35: 267-72.

97. Doig D, Hobson BM, Muller M, et al. Carotid Anatomy Does Not Predict the Risk of New Ischaemic Brain Lesions on Diffusion-Weighted Imaging after Carotid Artery Stenting in the ICSS-MRI Substudy. *Eur J Vasc Endovasc Surg*. 2016; 51: 14-20.

98. Gensicke H, van der Worp HB, Nederkoorn PJ, et al. Ischemic brain lesions after carotid artery stenting increase future cerebrovascular risk. *Journal of the American College of Cardiology*. 2015; 65: 521-9.

99. Rostamzadeh A, Zumbrunn T, Jongen LM, et al. Predictors of acute and persisting ischemic brain lesions in patients randomized to carotid stenting or endarterectomy. *Stroke*. 2014; 45: 591-4.

100. Feiwell RJ, Besmertis L, Sarkar R, Saloner DA and Rapp JH. Detection of clinically silent infarcts after carotid endarterectomy by use of diffusion-weighted imaging. *AJNR AmJNeuroradiol*. 2001; 22: 646-9.

101. Tomczak R, Wunderlich A, Liewald F, Stuber G and Gorich J. Diffusion-weighted MRI: detection of cerebral ischemia before and after carotid thromboendarterectomy. *JComputAssistTomogr*. 2001; 25: 247-50.

102. Muller M, Ciccotti P, Axmann C and Kreissler-Haag D. Embolic cerebral ischemia in carotid surgery: a model for human embolic stroke? *MedSciMonit*. 2003; 9: CR411-CR6.

103. Inoue T, Tsutsumi K, Maeda K, et al. Incidence of ischemic lesions by diffusion-weighted imaging after carotid endarterectomy with routine shunt usage. *NeurolMedChir (Tokyo)*. 2006; 46: 529-33.

104. Ogasawara K, Suga Y, Sasaki M, et al. Intraoperative microemboli and low middle cerebral artery blood flow velocity are additive in predicting development of cerebral ischemic events after carotid endarterectomy. *Stroke*. 2008; 39: 3088-91.

105. Soinne L, Helenius J, Tikkala I, et al. The effect of severe carotid occlusive disease and its surgical treatment on cognitive functions of the brain. *Brain Cogn*. 2008.

106. Hebb MO, Heiserman JE, Forbes KP, Zabramski JM and Spetzler RF. Perioperative ischemic complications of the brain after carotid endarterectomy. *Neurosurgery*. 2010; 67: 286-93.

107. Oikawa K, Ogasawara K, Saito H, et al. Combined measurement of cerebral and cerebellar blood flow on preoperative brain perfusion SPECT imaging predicts development of new cerebral ischemic events after endarterectomy for symptomatic unilateral cervical carotid stenosis. *Clinical nuclear medicine*. 2013; 38: 957-61.

108. Yoshida K, Kurosaki Y, Funaki T, et al. Surgical dissection of the internal carotid artery under flow control by proximal vessel clamping reduces embolic infarcts during carotid endarterectomy. *World neurosurgery*. 2014; 82: e229-34.

109. Cho J, Lee KK, Yun WS, Kim HK, Hwang YH and Huh S. Selective shunt during carotid endarterectomy using routine awake test with respect to a lower shunt rate. *Journal of the Korean Surgical Society*. 2013; 84: 238-44.

110. Sfyroeras GS, Bessias N, Moulakakis KG, et al. New cerebral ischemic lesions after carotid endarterectomy. *Annals of vascular surgery*. 2013; 27: 883-7.

111. Akpinar MB, Sahin V, Sahin N, et al. Previous chronic cerebral infarction is predictive for new cerebral ischemia after carotid endarterectomy. *J Cardiothorac Surg*. 2015; 10: 141.

112. Bourke VC, Bourke BM and Beiles CB. Operative Factors Associated with the Development of New Brain Lesions During Awake Carotid Endarterectomy. *Eur J Vasc Endovasc Surg*. 2016; 51: 167-73.

113. Zhang HP, Ma XD, Chen LF, Yang Y, Xu BN and Zhou DB. Cognitive Function After Carotid Endarterectomy: Early Decline and Later Recovery. *Turk Neurosurg*. 2016; 26: 833-9.

114. Grunwald IQ, Reith W, Karp K, et al. Comparison of stent free cell area and cerebral lesions after unprotected carotid artery stent placement. *EurJ VascEndovascSurg*. 2012; 43: 10-4.

115. Rosenkranz M, Thomalla G, Havemeister S, et al. Older age and greater carotid intima-media thickness predict ischemic events associated with carotid-artery stenting. *CerebrovascDis*. 2010; 30: 567-72.

116. Lovblad KO, Pluschke W, Remonda L, et al. Diffusion-weighted MRI for monitoring neurovascular interventions. *Neuroradiology*. 2000; 42: 134-8.

117. Jaeger HJ, Mathias KD, Hauth E, et al. Cerebral ischemia detected with diffusion-weighted MR imaging after stent implantation in the carotid artery. *AJNR AmJNeuroradiol*. 2002; 23: 200-7.

118. Rosenkranz M, Fiehler J, Niesen W, et al. The amount of solid cerebral microemboli during carotid stenting does not relate to the frequency of silent ischemic lesions. *AJNR AmJNeuroradiol*. 2006; 27: 157-61.

119. Peynircioglu B, Geyik S, Yavuz K, Cil BE, Saatci I and Cekirge S. Exclusion of atherosclerotic plaque from the circulation using stent-grafts: alternative to carotid stenting with a protection device? *CardiovascInterventRadiol*. 2007; 30: 854-60.

120. Jaeger H, Mathias K, Drescher R, et al. Clinical results of cerebral protection with a filter device during stent implantation of the carotid artery. *CardiovascInterventRadiol*. 2001; 24: 249-56.

121. Schluter M, Tubler T, Steffens JC, Mathey DG and Schofer J. Focal ischemia of the brain after neuroprotected carotid artery stenting. *JAmCollCardiol*. 2003; 42: 1007-13.

122. du Mesnil de RR, Schneider S, Yan B, Lehr A, Sitzer M and Berkefeld J. Diffusion-weighted MR imaging lesions after filter-protected stenting of high-grade symptomatic carotid artery stenoses. *AJNR AmJNeuroradiol*. 2006; 27: 1321-5.

123. Maleux G, Demaerel P, Verbeken E, et al. Cerebral ischemia after filter-protected carotid artery stenting is common and cannot be predicted by the presence of substantial amount of debris captured by the filter device. *AJNR AmJNeuroradiol*. 2006; 27: 1830-3.

124. McDonnell CO, Fearn SJ, Baker SR, Goodman MA, Price D and Lawrence-Brown MM. Value of diffusion-weighted MRI during carotid angioplasty and stenting. *EurJVascEndovascSurg*. 2006; 32: 46-50.

125. Pinero P, Gonzalez A, Mayol A, et al. Silent ischemia after neuroprotected percutaneous carotid stenting: a diffusion-weighted MRI study. *AJNR AmJNeuroradiol*. 2006; 27: 1338-45.

126. Asakura F, Kawaguchi K, Sakaida H, et al. Diffusion-weighted magnetic resonance imaging in carotid angioplasty and stenting with balloon embolic protection devices. *Neuroradiology*. 2006; 48: 100-12.

127. Asakura F, Kawaguchi K, Sakaida H, et al. Diffusion-weighted MR imaging in carotid angioplasty and stenting with protection by the reversed carotid arterial flow. *AJNR Am J Neuroradiol*. 2006; 27: 753-8.

128. Grunwald IQ, Supprian T, Politi M, et al. Cognitive changes after carotid artery stenting. *Neuroradiology*. 2006.

129. Schillinger M, Dick P, Wiest G, et al. Covered versus bare self-expanding stents for endovascular treatment of carotid artery stenosis: a stopped randomized trial. *JEndovascTher*. 2006; 13: 312-9.

130. Rapp JH, Wakil L, Sawhney R, et al. Subclinical embolization after carotid artery stenting: new lesions on diffusion-weighted magnetic resonance imaging occur postprocedure. *JVascSurg*. 2007; 45: 867-72.

131. Ghorab K, Macian F, Adoukounou T, Magy L, Chapot R and Vallat JM. Carotid angioplasty stenting revisited: clinical and radiological (MRI) outcome. *CerebrovascDis*. 2008; 25: 21-5.

132. Palombo G, Faraglia V, Stella N, Giugni E, Bozzao A and Taurino M. Late evaluation of silent cerebral ischemia detected by diffusion-weighted MR imaging after filter-protected carotid artery stenting. *AJNR AmJNeuroradiol*. 2008; 29: 1340-3.

133. Schofer J, Arendt M, Tubler T, Sandstede J and Schluter M. Late cerebral embolization after emboli-protected carotid artery stenting assessed by sequential diffusion-weighted magnetic resonance imaging. *JACCCardiovascInterv*. 2008; 1: 571-7.

134. Faggioli G, Ferri M, Rapezzi C, Tonon C, Manzoli L and Stella A. Atherosclerotic aortic lesions increase the risk of cerebral embolism during carotid stenting in patients with complex aortic arch anatomy. *JVascSurg*. 2008.

135. Tedesco MM, Dalman RL, Zhou W, Coogan SM, Lane B and Lee JT. Reduction of postprocedure microemboli following retrospective quality assessment and practice improvement measures for carotid angioplasty and stenting. *J VascSurg*. 2009; 49: 607-12.

136. Taha MM, Maeda M, Sakaida H, et al. Cerebral ischemic lesions detected with diffusion-weighted magnetic resonance imaging after carotid artery stenting: Comparison of several anti-embolic protection devices. *NeurolMedChir (Tokyo)*. 2009; 49: 386-93.

137. Faraglia V, Palombo G, Stella N, Rizzo L, Taurino M and Bozzao A. Cerebral embolization during transcervical carotid stenting with flow reversal: a diffusion-weighted magnetic resonance study. *AnnVasc Surg*. 2009; 23: 429-35.

138. Palombo G, Stella N, Faraglia V, et al. Cervical access for filter-protected carotid artery stenting: a useful tool to reduce cerebral embolisation. *EurJ VascEndovascSurg*. 2010; 39: 252-7.

139. Pinter L, Ribo M, Loh C, et al. Safety and feasibility of a novel transcervical access neuroprotection system for carotid artery stenting in the PROOF Study. *J Vasc Surg*. 2011; 54: 1317-23.

140. Uchiyama N, Misaki K, Mohri M, et al. Association between carotid plaque composition assessed by multidetector computed tomography and cerebral embolism after carotid stenting. *Neuroradiology*. 2012; 54: 487-93.

141. Tulip HH, Rosero EB, Higuera AJ, Ilarraza A, Valentine RJ and Timaran CH. Cerebral embolization in asymptomatic versus symptomatic patients after carotid stenting. *J Vasc Surg*. 2012; 56: 1579-84; discussion 84.

142. Leal I, Orgaz A, Flores A, et al. A diffusion-weighted magnetic resonance imaging-based study of transcervical carotid stenting with flow reversal versus transfemoral filter protection. *J Vasc Surg*. 2012; 56: 1585-90.

143. Palombo G, Stella N, Fantozzi C, Bozzao A and Taurino M. Transcranial Doppler and diffusion-weighted magnetic resonance evaluation of cerebral embolization occurring during transfemoral carotid stenting with proximal flow blockage. *J Cardiovasc Surg (Torino)*. 2012.

144. Takayama K, Taki W, Toma N, et al. Effect of pitavastatin on preventing ischemic complications with carotid artery stenting: a multicenter prospective study--EPOCH-CAS study. *Cardiovascular and interventional radiology*. 2014; 37: 1436-43.

145. Cano MN, Kambara AM, de Cano SJ, et al. Randomized comparison of distal and proximal cerebral protection during carotid artery stenting. *JACC Cardiovascular interventions*. 2013; 6: 1203-9.

146. Pini R, Faggioli G, Fittipaldi S, et al. Inflammatory mediators and cerebral embolism in carotid stenting: new markers of risk. *Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists*. 2013; 20: 684-94.

147. Park KY, Kim DI, Kim BM, et al. Incidence of embolism associated with carotid artery stenting: open-cell versus closed-cell stents. *Journal of neurosurgery*. 2013; 119: 642-7.

148. Patti G, Tomai F, Melfi R, et al. Strategies of clopidogrel load and atorvastatin reload to prevent ischemic cerebral events in patients undergoing protected carotid stenting. Results of the randomized ARMYDA-9 CAROTID (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting) study. *J AmCollCardiol*. 2013; 61: 1379-87.

149. Bijuklic K, Wandler A, Varnakov Y, Tuebler T and Schofer J. Risk factors for cerebral embolization after carotid artery stenting with embolic protection: a diffusion-weighted magnetic resonance imaging study in 837 consecutive patients. *Circulation Cardiovascular interventions*. 2013; 6: 311-6.

150. Castro-Afonso LH, Abud LG, Rolo JG, et al. Flow reversal versus filter protection: a pilot carotid artery stenting randomized trial. *CircCardiovasc Interv*. 2013; 6: 552-9.

151. Tanemura H, Maeda M, Ichikawa N, et al. High-risk plaque for carotid artery stenting evaluated with 3-dimensional T1-weighted gradient echo sequence. *Stroke*. 2013; 44: 105-10.

152. Gunduz Y, Akdemir R, Ayhan LT and Keser N. Can Doppler flow parameters of carotid stenosis predict the occurrence of new ischemic brain lesions detected by diffusion-weighted MR imaging after filter-protected internal carotid artery stenting? *AJNR American journal of neuroradiology*. 2014; 35: 760-5.

153. Huang KL, Chang YJ, Chang CH, et al. Impact of coexisting coronary artery disease on the occurrence of cerebral ischemic lesions after carotid stenting. *PLoS One*. 2014; 9: e94280.

154. Matsukawa H, Fujii M, Uemura A, et al. Pathology of embolic debris in carotid artery stenting. *Acta neurologica Scandinavica*. 2015; 131: 197-202.

155. Adhikari RB, Takeda M, Kolakshyapati M, et al. Somatosensory evoked potentials in carotid artery stenting: Effectiveness in ascertaining cerebral ischemic events. *J Clin Neurosci*. 2016; 30: 71-6.

156. Kuliha M, Roubec M, Goldirova A, et al. Laboratory-Based Markers as Predictors of Brain Infarction During Carotid Stenting: a Prospective Study. *J Atheroscler Thromb*. 2016; 23: 839-47.

157. Ruffino MA, Faletti R, Bergamasco L, Fonio P and Righi D. Incidence of New Ischaemic Brain Lesions After Carotid Artery Stenting with the Micromesh Roadsaver Carotid Artery Stent: A Prospective Single-Centre Study. *Cardiovascular and interventional radiology*. 2016; 39: 1541-9.

158. Gauvrit JY, Delmaire C, Henon H, et al. Diffusion/perfusion-weighted magnetic resonance imaging after carotid angioplasty and stenting. *JNeurol*. 2004; 251: 1060-7.

159. Cosottini M, Michelassi MC, Puglioli M, et al. Silent cerebral ischemia detected with diffusion-weighted imaging in patients treated with protected and unprotected carotid artery stenting. *Stroke*. 2005; 36: 2389-93.

160. Kastrup A, Groschel K, Nagele T, et al. Effects of age and symptom status on silent ischemic lesions after carotid stenting with and without the use of distal filter devices. *AJNR AmJNeuroradiol*. 2008; 29: 608-12.

161. El-Koussy M, Schroth G, Do DD, et al. Periprocedural embolic events related to carotid artery stenting detected by diffusion-weighted MRI: comparison between proximal and distal embolus protection devices. *J Endovasc Ther*. 2007; 14: 293-303.

162. Kim SJ, Roh HG, Jeon P, et al. Cerebral ischemia detected with diffusion-weighted MR imaging after protected carotid artery stenting: comparison of distal balloon and filter device. *Korean JRadiol*. 2007; 8: 276-85.

163. Bijuklic K, Wandler A, Hazizi F and Schofer J. The PROFI study (Prevention of Cerebral Embolization by Proximal Balloon Occlusion Compared to Filter Protection During Carotid Artery Stenting): a prospective randomized trial. *J AmCollCardiol*. 2012; 59: 1383-9.

164. Kopp CW, Steiner S, Nasel C, et al. Abciximab reduces monocyte tissue factor in carotid angioplasty and stenting. *Stroke*. 2003; 34: 2560-7.

165. Kim HJ, Lee HJ, Yang JH, et al. The influence of carotid artery catheterization technique on the incidence of thromboembolism during carotid artery stenting. *AJNR American journal of neuroradiology*. 2010; 31: 1732-6.

166. Flach HZ, Ouhlous M, Hendriks JM, et al. Cerebral ischemia after carotid intervention. *JEndovascTher*. 2004; 11: 251-7.

167. Garcia-Sanchez S, Millan-Torne M, Capellades-Font J, Muchart J, Callejas P and Vila-Moriente N. [Ischemic brain lesions following carotid revascularisation procedures: a comparative study using diffusion-weighted magnetic resonance imaging]. *RevNeurol*. 2004; 38: 1013-7.

168. Roh HG, Byun HS, Ryoo JW, et al. Prospective analysis of cerebral infarction after carotid endarterectomy and carotid artery stent placement by using diffusion-weighted imaging. *AJNR AmJNeuroradiol*. 2005; 26: 376-84.

169. Iihara K, Murao K, Sakai N, Yamada N, Nagata I and Miyamoto S. Outcome of carotid endarterectomy and stent insertion based on grading of carotid endarterectomy risk: a 7-year prospective study. *JNeurosurg*. 2006; 105: 546-54.

170. Poppert H, Wolf O, Theiss W, et al. MRI lesions after invasive therapy of carotid artery stenosis: a risk-modeling analysis. *NeurolRes*. 2006; 28: 563-7.

171. Lacroix V, Hammer F, Astarci P, et al. Ischemic cerebral lesions after carotid surgery and carotid stenting. *EurJVascEndovascSurg*. 2007; 33: 430-5.

172. Faraglia V, Palombo G, Stella N, et al. Cerebral embolization in patients undergoing protected carotid-artery stenting and carotid surgery. *JCardiovascSurg(Torino)*. 2007; 48: 683-8.

173. Tedesco MM, Coogan SM, Dalman RL, et al. Risk factors for developing postprocedural microemboli following carotid interventions. *JEndovascTher*. 2007; 14: 561-7.

174. Skjelland M, Krohg-Sorensen K, Tennoe B, Bakke SJ, Brucher R and Russell D. Cerebral microemboli and brain injury during carotid artery endarterectomy and stenting. *Stroke*. 2009; 40: 230-4.

175. Zhou W, Dinishak D, Lane B, Hernandez-Boussard T, Bech F and Rosen A. Long-term radiographic outcomes of microemboli following carotid interventions. *J VascSurg*. 2009; 50: 1314-9.

176. Bonati LH, Jongen LM, Haller S, et al. New ischaemic brain lesions on MRI after stenting or endarterectomy for symptomatic carotid stenosis: a substudy of the International Carotid Stenting Study (ICSS). *Lancet Neurol*. 2010; 9: 353-62.

177. Wasser K, Pilgram-Pastor SM, Schnaudigel S, et al. New brain lesions after carotid revascularization are not associated with cognitive performance. *J VascSurg*. 2011; 53: 61-70.

178. Yamada K, Yoshimura S, Kawasaki M, et al. Embolic complications after carotid artery stenting or carotid endarterectomy are associated with tissue characteristics of carotid plaques evaluated by magnetic resonance imaging. *Atherosclerosis*. 2011; 215: 399-404.

179. Felli MM, Alunno A, Castiglione A, et al. CEA versus CAS: short-term and mid-term results. *International angiology : a journal of the International Union of Angiology*. 2012; 31: 420-6.

180. Capoccia L, Sbarigia E, Rizzo A, Mansour W and Speziale F. Silent stroke and cognitive decline in asymptomatic carotid stenosis revascularization. *Vascular*. 2012; 20: 181-7.

181. Zhou W, Hitchner E, Gillis K, et al. Prospective neurocognitive evaluation of patients undergoing carotid interventions. *J Vasc Surg*. 2012; 56: 1571-8.

182. Akutsu N, Hosoda K, Fujita A and Kohmura E. A preliminary prediction model with MR plaque imaging to estimate risk for new ischemic brain lesions on diffusion-weighted imaging after endarterectomy or stenting in patients with carotid stenosis. *AJNR American journal of neuroradiology*. 2012; 33: 1557-64.

183. Mitsuoka H, Shintani T, Furuya H, Nakao Y and Higashi S. Ultrasonographic character of carotid plaque and postprocedural brain embolisms in carotid artery stenting and carotid endarterectomy. *Ann Vasc Dis*. 2011; 4: 106-9.

184. Kuliha M, Roubec M, Prochazka V, et al. Randomized clinical trial comparing neurological outcomes after carotid endarterectomy or stenting. *Br J Surg*. 2015; 102: 194-201.

185. Fleming TR and Powers JH. Biomarkers and surrogate endpoints in clinical trials. *Stat Med*. 2012; 31: 2973-84.

186. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. *StatMed*. 1989; 8: 431-40.

187. Carotid Stenting Trialists C, Bonati LH, Dobson J, et al. Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data. *Lancet*. 2010; 376: 1062-73.

188. Mullins ME, Schaefer PW, Sorensen AG, et al. CT and conventional and diffusion-weighted MR imaging in acute stroke: study in 691 patients at presentation to the emergency department. *Radiology*. 2002; 224: 353-60.

189. Fiebach JB, Schellinger PD, Jansen O, et al. CT and diffusion-weighted MR imaging in randomized order: diffusion-weighted imaging results in higher accuracy and lower interrater variability in the diagnosis of hyperacute ischemic stroke. *Stroke*. 2002; 33: 2206-10.

190. Giles MF, Albers GW, Amarenco P, et al. Addition of brain infarction to the ABCD2 Score (ABCD2I): a collaborative analysis of unpublished data on 4574 patients. *Stroke*. 2010; 41: 1907-13.

191. Al-Khaled M, Matthis C, Munte TF, Eggers J and Qug SSS. The incidence and clinical predictors of acute infarction in patients with transient ischemic attack using MRI including DWI. *Neuroradiology*. 2013; 55: 157-63.

192. Kastrup A, Ernemann U, Nagele T and Groschel K. Risk factors for early recurrent cerebral ischemia before treatment of symptomatic carotid stenosis. *Stroke*. 2006; 37: 3032-4.

193. Vermeer SE, Prins ND, den HT, Hofman A, Koudstaal PJ and Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. *NEnglJMed*. 2003; 348: 1215-22.

194. Restrepo L, Wityk RJ, Grega MA, et al. Diffusion- and perfusion-weighted magnetic resonance imaging of the brain before and after coronary artery bypass grafting surgery. *Stroke*. 2002; 33: 2909-15.

195. Barber PA, Hach S, Tippett LJ, Ross L, Merry AF and Milsom P. Cerebral ischemic lesions on diffusion-weighted imaging are associated with neurocognitive decline after cardiac surgery. *Stroke*. 2008; 39: 1427-33.

196. Altinbas A, van Zandvoort MJ, van den BE, et al. Cognition after carotid endarterectomy or stenting: a randomized comparison. *Neurology*. 2011; 77: 1084-90.